Related Experiment Video
Updated: May 31, 2026
06:47
Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
Published on: September 20, 2011
Paclitaxel-loaded polyester nanoparticles prepared by spray-drying technology: in vitro bioactivity evaluation
P López-Gasco1, I Iglesias, J Benedí
1Facultad de Farmacia, Departamento de Farmacología, Universidad Complutense de Madrid, Madrid, Spain.
Journal of Microencapsulation
|July 9, 2011
Summary
Paclitaxel (PTX) nanoparticles using PLGA and PCL polymers show high encapsulation efficiency and sustained release for cancer treatment. These drug-loaded nanoparticles effectively inhibit MCF7 cell proliferation and induce cell cycle arrest.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Pharmacology
Background:
- Paclitaxel (PTX) is a key chemotherapeutic agent for ovarian and breast cancers.
- Developing effective drug delivery systems is crucial for enhancing PTX efficacy and reducing side effects.
- Nanoparticle-based drug delivery offers potential for improved cancer therapy.
Purpose of the Study:
- To encapsulate Paclitaxel (PTX) into poly(lactide-co-glycolide) (PLGA) and poly(ε-caprolactone) (PCL) nanoparticles.
- To characterize the physicochemical properties and in vitro drug release of PTX-loaded nanoparticles.
- To evaluate the in vitro efficacy of PTX-loaded nanoparticles on MCF7 breast cancer cells.
Main Methods:
- Spray-drying technique for nanoparticle fabrication.
- Characterization of nanoparticle morphology, size distribution, and drug encapsulation efficiency.
- In vitro drug release studies over 35 days.
- Cytotoxicity and cell cycle analysis using MCF7 cells.
Main Results:
- Nanoparticles exhibited particle sizes between 0.8-1 µm with over 80% PTX incorporation efficiency.
- In vitro drug release showed sustained release over 35 days, with release rates: PCL > PLGA 50:50 > PLGA 75:25.
- Unloaded nanoparticles were cytocompatible.
- PTX-loaded nanoparticles effectively arrested MCF7 cells in the G2/M phase and reduced cell viability below 20%.
Conclusions:
- PLGA and PCL nanoparticles are suitable carriers for Paclitaxel delivery.
- The developed PTX-loaded nanoparticles demonstrate significant in vitro anticancer activity against MCF7 cells.
- These findings support the potential of PTX-loaded nanoparticles for breast cancer treatment.
